Oncology

Featured Research

CDC42 Suppression Blocks Leukemia Progression in Preclinical Tests Researchers have hunted for years to find ways to disrupt the uncanny survival and self-renewal abilities of acute myeloid leukemia (AML) cells. So far, experts have found very few specific signaling pathways that lead to a weakness that can be therapeutically exploited.